Combat Medical Highlights Patient Impact of HIVEC HEAT Trial at the American Urological Association Annual Meeting
MHRA-approved phase 3 study is investigating intravesical delivery of hyperthermic chemotherapy in bladder-sparing treatment of patients with non-muscle invasive bladder cancer
Study being conducted across 25 sites in the UK is designed to support FDA registration
Combat Medical (Combat), a medical device company optimising the delivery and efficacy of cancer therapeutics, today announced an update on its HIVEC® HEAT FDA registration trial at The American Urological Association (AUA) Annual Meeting. Underscoring the potential of the study to expand bladder-preserving treatment options for cancer patients, Professor Leyshon Griffiths, the trial’s Chief Investigator, provided an update, outlining the study design and recruitment process.
For patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (NMIBC), radical cystectomy remains the standard treatment. The Combat bladder recirculation system (BRS), developed using the Company’s patented hyperthermic platform technology, delivers chemotherapy at precisely controlled temperatures with the aim of increasing anti-tumour activity while offering an alternative bladder-preserving treatment approach and an improved quality of life for patients.
